The delegation of the multinational pharmaceutical giant alliance has been staying in a hotel in the Nandu Provincial City for several days.
"He’s crazy!" Thompson was the first to speak, "Complete control of core technology? Disclosing all pricing data? This completely goes against comrcial logic!"
"But what he says is true." Sato Kenichi said calmly, "If we don’t cooperate, we may indeed be excluded from the next generation of treatnt systems."
"We can jointly develop alternative technology to counter this." Another representative suggested.
"How long will it take? Five years? Ten years?" Isabelle Moro, a representative from a European pharmaceutical company, shook her head, "I’ve carefully studied Yang Ping’s papers, their technological route is completely different from ours, it’s a true innovation, replicating it in a short ti is almost impossible."
Schneider rubbed his temples: "The key issue is whether we really need to maintain a united front? Huang Jiacai is right, under the inclusive frawork we are actually competing to beco partners, not joint controllers. If the six of us continue to bundle together, he may choose to collaborate with other small and dium-sized companies, which would cause us greater losses. No matter what, we must secure an entry ticket to this future market."
"So your suggestion is... separate negotiations?" Dupont asked.
"At the very least, we need to maintain flexibility." Schneider said, "We can reach a gentleman’s agreent: coordinate on core terms like the pricing floor and regional division, but each company can explore diverse cooperation thods."
"I agree." Sato imdiately stated, "We are willing to offer more competitive solutions in process optimization and Asian production."
"But this way we will end up in a bidding war with each other, and in the end, Ruixing will benefit the most." Thompson opposed.
"Or we continue to jointly apply pressure," Dr. Moro proposed, "but adjust the goals: not to control the technology, but to secure more favorable licensing terms. For example, extend the licensing period, reduce licensing fees, and have more say in the decision-making process."
Ultimately, the six giants reached an internal morandum: maintain an image of "consulting consensus" externally, but in actual operations, allow companies to conduct differentiated negotiations with Ruixing based on their own advantages. anwhile, they will jointly pressure Ruixing to seek "reasonable adjustnts" to certain terms of the inclusive frawork.
Negotiations restarted.
"Mr. Huang," Schneider represented the spokesperson, "After discussion, we are willing to explore cooperation under the inclusive frawork. But several issues need to be addressed: First, the licensing period should be no less than 15 years; second, partners should enjoy a certain market protection period within their regions; third, the pricing chanism needs more flexibility, especially for countries with different healthcare systems; fourth, we wish to establish a joint steering committee, where partners have substantive advisory rights."
Huang Jiacai listened and nodded slightly: "These issues we can discuss, and I need to reiterate our core principles: control over core technology, global pricing transparency, non-exclusivity principle. As long as you adhere to these three core principles, Ruixing is willing to engage in constructive dialogue with you."
After exchanging glances, Schneider said, "Alright, we continue discussing so cooperation details."...
Two hours later, Huang Jiacai glanced at the ti: "We’ve talked a lot today, I suggest we continue tomorrow. We can discuss specific clauses item by item. Additionally, tomorrow afternoon, mbers of Professor Yang Ping’s team will co from the laboratory to engage in technical exchanges with all of you."
This news reenergized the representatives. eting mbers of Professor Yang Ping’s team ant a more direct understanding of technological details, which also indicated Ruixing’s serious consideration of cooperation.
The eting ended, and the delegation left.
Huang Jiacai remained alone in the eting room, as his assistant walked in.
"President Huang, a reporter from the Wall Street Journal wishes to interview about these negotiations."
"No response for now." Huang Jiacai said.
...
Washington, East Wing of the White House.
In the Oval Office, a special eting concerning life and death was underway. This is not a routine national security eting, yet it might affect the future position of the United States in the biotechnology field.
"Mr. President, the data is right here." Dr. Allen Wilson, Director of the National Institutes of Health (NIH), placed a thick report on the oak desktop, "Clinical trial data provided by Sanbo Research Institute, confird with our most rigorous double-blind review, showed an efficacy rate of 92%, while the current standard therapeutic rate averages only 19%. The serious adverse reaction rate is 1.2%, well below the FDA’s standard approval red line of 5%."
The President reviewed the report, brows furrowed. Being a lawyer, he maintained an instinctive caution towards scientific data, but the graphs and statistical significance markings (p
User Comments
0 comments from readers